Akers Biosciences, Inc. Update RE Admission of Shares (8088B)
January 15 2018 - 2:00AM
UK Regulatory
TIDMAKR
RNS Number : 8088B
Akers Biosciences, Inc.
15 January 2018
January 15, 2018
Akers Biosciences, Inc.
Update Re: Admission of Shares
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers
Bio" or the "Company"), a developer of rapid health information
technologies, provides an update on the admission of shares
previously announced in the Issue of Equity announcements dated
October 19, 2017, October 20, 2017 and December 22, 2017.
The Company has now applied for the admission to trading on AIM
of the aggregate 295,107 restricted common shares of no par value
referred to in the October 19 and October 20, 2017 announcements;
together with the 6,000,000 common shares of no par value referred
to in the December 22, 2017 announcement. Admission of these shares
is expected to take place on January 17, 2018 ("Admission").
Following Admission, the Company's issued share capital will
consist of 54,753,887 common shares with no common shares held in
treasury. Therefore, the above figure of 54,753,887 may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the FCA's
Disclosure and Transparency Rules. Shareholders should note that
the figure of 54,753,887 shares includes those shares described in
the announcement dated January 12, 2018.
About Akers Biosciences, Inc.
Akers Bio develops, manufactures, and supplies rapid screening
and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
For more information:
Akers Biosciences, Inc.
John J. Gormally, Chief Executive Officer
Raymond F. Akers, Jr. PhD, Executive Chairman and Chief
Scientific Director
Tel. +1 856 848 8698
finnCap (UK Nominated Adviser and Broker)
Adrian Hargrave / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Vigo Communications (Global Public Relations)
Ben Simons / Fiona Henson / Emma Lord
Tel. +44 (0)20 7830 9704
Email: akers@vigocomms.com
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEDBGDBIGBBGIS
(END) Dow Jones Newswires
January 15, 2018 02:00 ET (07:00 GMT)
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2023 to Apr 2024